Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631

PURPOSE: The Children’s Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. PATIENTS AND...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Kutny, Matthew A., Alonzo, Todd A., Gerbing, Robert B., Wang, Yi-Cheng, Raimondi, Susana C., Hirsch, Betsy A., Fu, Cecilia H., Meshinchi, Soheil, Gamis, Alan S., Feusner, James H., Gregory, John J.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2017
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5590801/
https://ncbi.nlm.nih.gov/pubmed/28767288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.6183
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы